Radiation enhances the delivery of antisense oligonucleotides and improves chemo-radiation efficacy in brain tumor xenografts
Authors:
Open Access
- 14 April 2021
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 29 (5) , 533-542
Abstract
Overexpression of O6-methylguanine DNA methyltransferase (MGMT) contributes to resistance to chemo-radiation therapy (CRT) in brain tumors. We previously demonstrated that non-ablative radiation improved delivery of anti-MGMT morpholino oligonucleotides (AMONs) to reduce MGMT levels in subcutaneous tumor xenografts. We evaluate this approach to enhance CRT efficacy in rat brain tumor xenograft models. The impact of radiation on targeted delivery was evaluated using fluorescent oligonucleotides (f-ON). In vitro, f-ON was localized to clathrin-coated vesicles, endosomes, and lysosomes using confocal microscopy in T98G glioma cells. In vivo, fluorescence was detected in pre-radiated, but not non-radiated Long Evans (non-tumor bearing) rat brains. Cranial radiation (2 Gy) followed by AMONs (intravenous, 10.5 mg/kg) reduced MGMT expression by 50% in both orthotopic cerebellar D283 medulloblastoma and intracerebral H460 non-small cell lung carcinoma (NSCLC) xenograft models. To evaluate the efficacy, AMONs concurrent with CRT (2 Gy radiation plus oral 20 mg/kg temozolomide ×4 days) reduced tumor volumes in the medulloblastoma model (p = 0.012), and a similar trend was found in the NSCLC brain metastasis model. We provide proof of concept for the use of non-ablative radiation to guide and enhance the delivery of morpholino oligonucleotides into brain tumor xenograft models to reduce MGMT levels and improve CRT efficacy.Keywords
Funding Information
- Foundation for the National Institutes of Health (CA137488, CA199111)
- Walter S. and Lucienne Driskill Foundation
- Veterans Administration Merit Review grant
This publication has 43 references indexed in Scilit:
- Drug transport in brain via the cerebrospinal fluidFluids and Barriers of the CNS, 2011
- Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast CancerClinical Cancer Research, 2010
- Growth of Peripheral and Central Nervous System Tumors Is Supported by Cytoplasmic c-Fos in Humans and MicePLOS ONE, 2010
- Tumor O6-methylguanine-DNA Methyltransferase Inactivation by Oral LomeguatribClinical Cancer Research, 2010
- Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant gliomaNeuro-Oncology, 2009
- Radiosensitizing Effects of Temozolomide Observed in vivo only in a Subset of O6-Methylguanine-DNA Methyltransferase Methylated Glioblastoma Multiforme XenograftsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant GliomaJournal of Clinical Oncology, 2009
- Phase I Trial of Polifeprosan 20 With Carmustine Implant Plus Continuous Infusion of Intravenous O6-Benzylguanine in Adults With Recurrent Malignant Glioma: New Approaches to Brain Tumor Therapy CNS Consortium TrialJournal of Clinical Oncology, 2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Contribution of O6‐methylguanine‐DNA methyltransferase to resistance to 1,3‐(2‐chloroethyl)‐1‐nitrosourea in human brain tumor‐derived cell linesMolecular Carcinogenesis, 1995